A man with severe, treatment-resistant epidermolysis bullosa acquisita (EBA) experienced sustained clinical remission for at least five years after…
Articles by Andrea Lobo, PhD
Rigosertib may hold promise for recessive dystrophic epidermolysis bullosa (RDEB) associated with advanced squamous cell carcinoma (SCC), with…
A new mutation in the ITGA6 gene, called “a novel lethal variant” by researchers, was identified as the cause of…
Lesions in the skin and mucosa in a 20-year-old woman with epidermolysis bullosa acquisita (EBA) came back years later, after…
LifeArc and DEBRA Austria have launched a £2.5 million (around $3.3 million) funding call for projects that seek…
The U.S. Food and Drug Administration (FDA) has approved a clinical trial in healthy volunteers of ZKN-013, a treatment…
The 6th annual Plunge for Elodie is set to raise more than $2 million for epidermolysis bullosa (EB)…